BRC Stock Analysis: Brady | NYSE
Security & Protection Services | NYSE, USA | Market Cap: 3.827m USD | 12M Return: 6.6% | US1046741062 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.8M
EPS Trend: 99.2%
Qual. Beats: 0
Rev. Trend: 97.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Brady Corporation (NYSE: BRC) is a Milwaukee-based manufacturer founded in 1914 that produces identification solutions and workplace safety products for customers across the Americas, Asia, Europe, and Australia. Its product portfolio spans safety and traffic signs, floor-marking tapes, pipe markers, lockout/tagout devices, personal protective equipment, first aid supplies, RFID and barcode scanners, handheld printers, wire markers, and patient identification wristbands used in hospital and laboratory settings. The company serves a broad range of end markets, including industrial and electronic manufacturing, healthcare, chemical, oil and gas, automotive, aerospace, government, construction, utilities, retail, and telecommunications. Products are sold through a multi-channel distribution model that combines third-party distributors, a direct sales force, and digital channels. Within the Industrials sector and the Commercial Printing sub-industry (per GICS classification), Brady operates as a niche specialty printer and label supplier, where its offerings are often tied to regulatory compliance, asset tracking, and workplace safety standards, which tend to create recurring demand from existing customers.
- Workplace Safety segment growth accelerates following Accidental Health & Safety acquisition
- European industrial weakness pressures identification solutions organic revenue
- Pricing actions and productivity initiatives expand operating margins
| Net Income: 205.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.54 > 1.0 |
| NWC/Revenue: 20.04% < 20% (prev 19.26%; Δ 0.78% < -1%) |
| CFO/TA 0.13 > 3% & CFO 244.1m > Net Income 205.4m |
| Net Debt (-34.9m) to EBITDA (314.0m): -0.11 < 3 |
| Current Ratio: 1.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.8m) vs 12m ago -0.06% < -2% |
| Gross Margin: 51.75% > 18% (prev 50.27%; Δ 1.48% > 0.5%) |
| Asset Turnover: 92.66% > 50% (prev 87.28%; Δ 5.39% > 0%) |
| Interest Coverage Ratio: 27.75 > 6 (EBIT TTM 269.1m / Interest Expense TTM 9.70m) |
| A: 0.18 (Total Current Assets 688.5m - Total Current Liabilities 355.5m) / Total Assets 1.85b |
| B: 0.80 (Retained Earnings 1.48b / Total Assets 1.85b) |
| C: 0.15 (EBIT TTM 269.1m / Avg Total Assets 1.79b) |
| D: 2.75 (Book Value of Equity 1.36b / Total Liabilities 494.4m) |
| Altman-Z'' = 7.67 = AAA |
| DSRI: 1.02 (Receivables 260.9m/231.9m, Revenue 1.66b/1.51b) |
| GMI: 0.97 (GM 50.27% / 51.75%) |
| AQI: 0.95 (AQ_t 0.45 / AQ_t-1 0.48) |
| SGI: 1.10 (Revenue 1.66b / 1.51b) |
| TATA: -0.02 (NI 205.4m - CFO 244.1m) / TA 1.85b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of October 29, 2026, the stock is trading at USD 81.86 with a total of 198,161 shares traded. Over the past week, the price has changed by -0.58%, over one month by -2.37%, over three months by -15.98% and over the past year by +6.59%.
Current recommended Stop Loss: 79.00 (which is 3.5% or 1.5 ATR below the current price).
Brady has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy BRC.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 110 | 34.4% |
P/E Trailing = 18.9744
P/E Forward = 15.361
P/S = 2.303
P/B = 3.0204
P/EG = 1.6733
Revenue TTM = 1.66b USD
EBIT TTM = 269.1m USD
EBITDA TTM = 314.0m USD
Long Term Debt = 15.0m USD (from longTermDebt, last quarter)
Short Term Debt = 17.0m USD (from shortTermDebt, last quarter)
Debt = 152.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 68.6m
Net Debt = -34.9m USD (calculated: Debt 152.2m - CCE 187.1m)
Enterprise Value = 3.79b USD (3.83b + Debt 152.2m - CCE 187.1m)
Interest Coverage Ratio = 27.75 (Ebit TTM 269.1m / Interest Expense TTM 9.70m)
EV/FCF = 19.68x (Enterprise Value 3.79b / FCF TTM 192.7m)
FCF Yield = 5.08% (FCF TTM 192.7m / Enterprise Value 3.79b)
FCF Margin = 11.59% (FCF TTM 192.7m / Revenue TTM 1.66b)
Net Margin = 12.36% (Net Income TTM 205.4m / Revenue TTM 1.66b)
Gross Margin = 51.75% ((Revenue TTM 1.66b - Cost of Revenue TTM 801.7m) / Revenue TTM)
Gross Margin QoQ = 52.90% (prev 51.80%)
Tobins Q-Ratio = 2.05 (Enterprise Value 3.79b / Total Assets 1.85b)
Interest Expense / Debt = 6.37% (Interest Expense 9.70m / Debt 152.2m)
Taxrate = 20.83% (54.0m / 259.4m)
NOPAT = 213.1m (EBIT 269.1m * (1 - 20.83%))
Current Ratio = 1.94 (Total Current Assets 688.5m / Total Current Liabilities 355.5m)
Debt / Equity = 0.11 (Debt 152.2m / totalStockholderEquity, last quarter 1.36b)
Debt / EBITDA = -0.11 (Net Debt -34.9m / EBITDA 314.0m)
Debt / FCF = -0.18 (Net Debt -34.9m / FCF TTM 192.7m)
Total Stockholder Equity = 1.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.45% (Net Income 205.4m / Total Assets 1.85b)
RoE = 15.62% (Net Income TTM 205.4m / Total Stockholder Equity 1.31b)
RoCE = 20.24% (EBIT 269.1m / Capital Employed (Equity 1.31b + L.T.Debt 15.0m))
RoIC = 14.90% (NOPAT 213.1m / Invested Capital 1.43b)
WACC = 7.94% (E(3.83b)/V(3.98b) * Re(8.06%) + D(152.2m)/V(3.98b) * Rd(6.37%) * (1-Tc(0.21)))
Discount Rate = 8.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.65 | Cagr: -0.59%
[DCF] Terminal Value 77.97% ; FCFF base≈177.0m ; Y1≈202.9m ; Y5≈298.7m
[DCF] Fair Price = 104.5 (EV 4.49b - Net Debt -34.9m = Equity 4.53b / Shares 43.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.16 | EPS CAGR: 11.54% | SUE: 0.18 | # QB: 0
Revenue Correlation: 97.69 | Revenue CAGR: 9.00% | SUE: 0.79 | # QB: 0
EPS current Quarter (2026-10-31): EPS=1.51 | Chg30d=-3.51% | Revisions=+40% | Analysts=2
EPS next Quarter (2027-01-31): EPS=1.43 | Chg30d=-3.39% | Revisions=+25% | Analysts=2
EPS current Year (2027-07-31): EPS=6.55 | Chg30d=-0.08% | Revisions=+25% | GrowthEPS=+23.8% | GrowthRev=+74.0%
EPS next Year (2028-07-31): EPS=7.21 | Chg30d=+0.49% | Revisions=+25% | GrowthEPS=+10.2% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: +62% (up=5, down=0)